基于CiteSpace的生脉类中成药治疗心血管疾病知识图谱可视化分析

Visualization analysis of knowledge map of Shengmai-based Chinese patent medicines in the treatment of cardiovascular diseases based on CiteSpace

关键词:  生脉  心血管疾病  文献计量  进展分析

Key words:  Shengmai  cardiovascular diseases  bibliometrics  research trends

摘要:

[目的] 了解生脉类中成药治疗心血管疾病的临床及药理研究现状，分析该领域的热点、前沿和发展趋势。[方法] 检索中国知网数据库（CNKI）、维普（VIP）、万方（WangFang）中有生脉类中成药治疗心血管疾病的文献为文献样本，基于文献计量学，利用Citespace软件对该领域文献进行作者、机构以及关键词等分析，并通过气泡图方式展现干预措施以及结局指标的分布。[结果] 共纳入相关文献665篇，生脉注射液作为生脉类中成药的其中一种，研究文献相关性最高；生脉类中成药多用于治疗心力衰竭、冠心病等心血管疾病，结局指标多关注于临床疗效、心功能评价。[结论] 综合分析表明，生脉类中成药治疗心血管疾病研究领域形成了多个核心作者团体，但缺乏跨团队间的合作，建议进一步跨区域的合作交流；关键词分析结果显示药理研究与临床研究紧密结合，本领域主要研究内容可分为疾病类型研究、中西医结合疗法、机制研究、结局指标分布等4类，热点主要关注在“临床疗效”，对于心肌细胞“凋亡”和生脉类中成药对心脏的保护作用为代表的机制研究将成为未来研究热点，也是目前研究的前沿方向。

Abstract:

[Objective] To investigate the current status of clinical and pharmacological research on Shengmai-based Chinese patent medicines for cardiovascular diseases，and to identify the hotspots，frontiers，and development trends in this field. [Methods] Relevant literature on Shengmai-based Chinese patent medicines for cardiovascular diseases was retrieved from the China National Knowledge Infrastructure（CNKI） database. Bibliometric analyses of authors，institutions，and keywords were conducted using CiteSpace software，and the distribution of intervention measures and outcome indicators was illustrated by bubble charts. [Results] A total of 665 articles were included. Among Shengmai-based medicines，Shengmai Injection had the highest number of related studies. These medicines were mainly applied to cardiovascular diseases such as heart failureand coronary heart disease. Outcome indicators primarily focused on clinical efficacy and cardiac function evaluation. [Conclusion] Comprehensive analysis reveals multiple core author groups in the research field of Shengmai-based Chinese patent medicines for cardiovascular diseases；however，cross-team collaboration remains insufficient. Enhanced cross-regional cooperation and communication are recommended. Keyword analysis demonstrates close integration between pharmacological and clinical research. Research topics primarily include disease-specific studies，integrated traditional Chinese and Western medicine therapies，mechanism exploration，and distribution of outcome indicators. Clinical efficacy remains the primary hotspot，whereas mechanism studies represented by myocardial apoptosis and cardiac protection effects of Shengmai-based medicines represent emerging hotspots and frontiers for future research.